Zevra Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Zevra Therapeutics has a total shareholder equity of $61.9M and total debt of $42.8M, which brings its debt-to-equity ratio to 69.1%. Its total assets and total liabilities are $172.3M and $110.5M respectively.
Key information
69.1%
Debt to equity ratio
US$42.77m
Debt
| Interest coverage ratio | n/a |
| Cash | US$67.74m |
| Equity | US$61.86m |
| Total liabilities | US$110.46m |
| Total assets | US$172.33m |
Recent financial health updates
Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08
Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11Recent updates
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate
May 26Financial Position Analysis
Short Term Liabilities: ZVRA's short term assets ($86.9M) exceed its short term liabilities ($73.7M).
Long Term Liabilities: ZVRA's short term assets ($86.9M) exceed its long term liabilities ($36.7M).
Debt to Equity History and Analysis
Debt Level: ZVRA has more cash than its total debt.
Reducing Debt: ZVRA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZVRA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ZVRA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.